Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Penny Whiting,Penny Whiting,Robert Wolff,Sohan Deshpande,Marcello Di Nisio,Steven Duffy,Adrian V. Hernandez,Adrian V. Hernandez,J. Christiaan Keurentjes,Shona H. Lang,Kate Misso,Steve Ryder,Simone Schmidlkofer,Marie Westwood,Jos Kleijnen +14 more
Reads0
Chats0
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.Abstract:
Importance Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. Objective To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. Data Sources Twenty-eight databases from inception to April 2015. Study Selection Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. Data Extraction and Synthesis Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. Main Outcomes and Measures Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. Results A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], −0.46 [95% CI, −0.80 to −0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, −0.12 [95% CI, −0.24 to 0.01]; 5 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. Conclusions and Relevance There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.read more
Citations
More filters
Journal ArticleDOI
Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review.
TL;DR: Novel experimental findings will be summarized and recent advances in understanding the mechanisms of CB1-dependent cannabinoid signaling being relevant for central regulation of feeding behavior will be highlighted.
Journal ArticleDOI
The cannabis crop
TL;DR: Cannabis is one of humanity's oldest cultivated crops, but despite its long history and many uses, hard facts on its evolution and impact on the human body are in short supply.
Journal ArticleDOI
Cannabinoids: Therapeutic Use in Clinical Practice
TL;DR: The potential therapeutic efficacy of natural and synthetic cannabinoids and their clinical relevance in cancer, neurodegenerative and dermatological diseases, and viral infections are highlighted.
Journal ArticleDOI
The Use of Medical Marijuana in Cancer.
TL;DR: The use of medical marijuana in cancer care presents a dilemma for both patients and physicians and the current state of the research is addressed, including potential indications, risks and adverse effects, preliminary data on anticancer effects, as well as legal and quality issues.
Journal ArticleDOI
Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process.
Arun Bhaskar,Alan Bell,Michael Boivin,Wellington Briques,Matthew R.D. Brown,Matthew R.D. Brown,Hance Clarke,Claude Cyr,Elon Eisenberg,Ricardo Ferreira de Oliveira Silva,Eva Frohlich,Peter Georgius,Malcolm Hogg,Malcolm Hogg,Tina Ingrid Horsted,Caroline A. MacCallum,Kirsten R. Müller-Vahl,Colleen O'Connell,Robert Sealey,Marc Seibolt,Aaron Sihota,Brennan K Smith,Dustin Sulak,Antonio Vigano,Dwight E. Moulin +24 more
TL;DR: Using a multistage modified Delphi process, twenty global experts across nine countries developed consensus-based recommendations on how to dose and administer medical cannabis in patients with chronic pain this paper, which may be considered for patients experiencing neuropathic, inflammatory, nociplastic, and mixed pain.
References
More filters
Journal ArticleDOI
Meta-Analysis in Clinical Trials*
TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Book
Cochrane Handbook for Systematic Reviews of Interventions
Julian P T Higgins,Sally Green +1 more
TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.